• Colorectal liver metastases
• Magnetic resonance imaging
• Multidetector computed tomography
• Radiofrequency ablation

• Humans
• Liver Neoplasms/secondary
• Liver Neoplasms/diagnostic imaging
• Liver Neoplasms/surgery
• Colorectal Neoplasms/pathology
• Male
• Female
• Middle Aged
• Tomography, X-Ray Computed/methods
• Aged
• Retrospective Studies
• Radiofrequency Ablation/methods
• Follow-Up Studies
• Treatment Outcome
• Neoplasm Recurrence, Local
• Magnetic Resonance Imaging/methods
• Adult
• Aged, 80 and over
• Surgery, Computer-Assisted/methods
• Catheter Ablation/methods

• Interventional oncology
• Liver neoplasms
• Microwave ablation

• Hepatocellular carcinoma
• efficacy
• gallbladder
• liver metastases
• radiofrequency ablation
• safety

To analyze long-term oncological outcomes of open and percutaneous thermal ablation in the treatment of patients with colorectal liver metastases (CRLM).

This assessment from a prospective, longitudinal tumor registry included 329 patients who underwent 541 procedures for 1350 CRLM from January 2010 to February 2021. Three cohorts were formed: 2010–2013 (129 procedures [53 percutaneous]), 2014–2017 (206 procedures [121 percutaneous]) and 2018–2021 (206 procedures [135 percutaneous]). Local tumor progression-free survival (LTPFS) and overall survival (OS) data were estimated using the Kaplan–Meier method. Potential confounding factors were analyzed with uni- and multivariable Cox regression analyses.

LTPFS improved significantly over time for percutaneous ablations (2-year LTPFS 37.7% vs. 69.0% vs. 86.3%, respectively, P < .0001), while LTPFS for open ablations remained reasonably stable (2-year LTPFS 87.1% [2010–2013], vs. 92.7% [2014–2017] vs. 90.2% [2018–2021], P = .12). In the latter cohort (2018–2021), the open approach was no longer superior regarding LTPFS (P = .125). No differences between the three cohorts were found regarding OS (P = .088), length of hospital stay (open approach, P = .065; percutaneous approach, P = .054), and rate and severity of complications (P = .404). The rate and severity of complications favored the percutaneous approach in all three cohorts (P = .002).

Over the last 10 years efficacy of percutaneous ablations has improved remarkably for the treatment of CRLM. Oncological outcomes seem to have reached results following open ablation. Given its minimal invasive character and shorter length of hospital stay, whenever feasible, percutaneous procedures may be favored over an open approach.

The online version contains supplementary material available at 10.1007/s00270-022-03152-9.

• Colorectal liver metastases (CRLM)
• Local tumor progression-free survival (LTPFS)
• Long-term oncological outcomes
• Microwave ablation (MWA)
• Radiofrequency ablation (RFA)

To compare the feasibility and efficacy of radiofrequency ablation (RFA) combined with chemotherapy and chemotherapy alone in patients with ovarian cancer liver metastasis (OCLM).

In this retrospective study, a total of 60 patients diagnosed with OCLM between May 2015 to February 2017 were included. All patients with ovarian cancer received chemotherapy and primary cytoreductive surgery before. Thirty patients underwent RFA and chemotherapy, and thirty patients only took chemotherapy. The overall survival (OS), CA-125 levels, and serum AST and ALT levels were compared between the two groups.

In the RFA group, the 1-,2-, and 3-year OS rates after RFA were 93.3%, 80.0%, and 53.3%, respectively. Serum AST and ALT levels were both elevated after RFA (p=0.0004, p<0.0001). In the chemotherapy group, the 1-,2-, and 3-year OS rates were 79.5%, 60.1%, and 42.1%, respectively. Levels of serum AST and ALT were stable. CA-125 levels for both groups were also available.

Based on our analysis of a single institution’s series of patients with OCLM, RFA could be a feasibly effective option in the management of OCLM.

• chemotherapy
• combined therapy
• ovarian cancer liver metastasis
• radiofrequency ablation
• survival analysis

• Colorectal cancer
• liver metastases
• liver resection
• percutaneous ablation

• Biological Factors
• Catheter Ablation/methods
• Colorectal Neoplasms/pathology
• Humans
• Liver Neoplasms/therapy
• Prospective Studies
• Treatment Outcome

• P30 CA016672 NCI NIH HHS
• R01 CA235564 NCI NIH HHS

• Colorectal cancer
• Prognosis
• TESTIN

• CRLM
• Colorectal liver metastases
• MWA
• Postoperative outcomes
• RFA
• Surgery

• Ablation techniques
• adjuvant chemotherapy
• liver metastasis
• pancreatic ductal adenocarcinoma
• prognosis

This study investigated the functional mechanism of transmembrane protein 100 (TMEM100) as a tumor inhibitor gene in CRC cells and offered a reference for the treatment of CRC.

The mRNA expression data of CRC were acquired from the TCGA database to mine differentially expressed mRNAs. The role of TMEM100 in the progression of CRC cells was evaluated by MTT, colony formation, scratch healing, and Transwell assays. The influence of TMEM100 on the TGF-β signaling pathway was detected by western blot.

TMEM100 was markedly lowly expressed in CRC. CRC cell growth was significantly suppressed by overexpressing TMEM100 but noticeably facilitated by silencing TMEM100. Overexpression of TMEM100 inhibited the activation of the TGF-β signaling pathway, thus inhibiting malignant progression of CRC.

TMEM100 is lowly expressed in CRC, which can suppress CRC cell growth by regulating the TGF-β signaling pathway.

• Radiofrequency ablation
• ablation time
• electrode tip
• large vessel
• liver

• Colorectal neoplasms
• magnetic resonance imaging
• progression-free survival
• radiofrequency ablation

To compare the therapeutic outcomes between open surgical resection (OSR) and percutaneous microwave ablation (PMWA) for colorectal liver metastasis (CRLM) ≤3 cm.

In this retrospective study, 200 consecutive patients with 306 CRLMs were reviewed. Overall survival (OS), disease-free survival (DFS), local tumour progression (LTP), intrahepatic distant recurrence, and extrahepatic metastasis were analysed to compare the therapeutic efficacy. Cox proportional hazards regression analysis was used to identify the prognostic factors for OS and DFS. Major complications and postoperative hospital stay were also assessed.

The 1-, 3-, and 5-year OS rates were 91.6%, 64.1%, and 46.3%, respectively, in the PMWA group and 89.7%, 62.4% and 44.7%, respectively, in the OSR group (P=0.839). The 1-, 3-, and 5-year DFS rates were 61.9%, 44.8%, and 41.3%, respectively, in the PMWA group and 58.1%, 24.4%, and 18.3%, respectively, in the OSR group (P =0.066). The two groups had comparable 5-year cumulative rates of intrahepatic distant recurrence (P=0.627) and extrahepatic metastasis (P=0.884). The 5-year cumulative LTP rate was lower in the OSR group than in the PMWA group (P=0.023). The rate of major complications was higher in the OSR group than in the PMWA group (P =0.025), and the length of hospital stay after treatment was shorter in the PMWA group (P<0.001).

There were no significant differences in OS or DFS between the two groups. PMWA was associated with increased LTP, fewer postoperative days and fewer major complications.

• ablation
• colorectal cancer
• liver metastasis
• resection
• ultrasound

To compare long-term outcomes of percutaneous radiofrequency ablation for colorectal liver metastases in perivascular versus non-perivascular locations.

This retrospective study included 388 consecutive patients with colorectal liver metastases (246 men, 142 women; age range 27–86 years) who underwent percutaneous radiofrequency ablation between January 2006 and December 2018. Propensity-score matching was performed for groups with perivascular and non-perivascular colorectal liver metastases. Rates of accumulative local tumor progression, overall survival, intra/extrahepatic recurrence, and complications were compared between the two groups.

We successfully matched 104 patients each in the perivascular and non-perivascular groups (mean age: 60.1 ± 11.5 and 60.1 ± 11.3 years, respectively). Cumulative local tumor progression rates at 6 months, 1 years, 3 years, and 5 years, respectively, were 8.8%,14.8%, 18.9%, and 18.9% in the perivascular group and 8.8%, 13.1%, 15.5%, and 15.5% in the non-perivascular group. The 1-, 3-, 5-, and 10-year overall survival rates, respectively, were 91.3%, 45.6%, 23.9%, and 18.7% in the perivascular group and 88.0%, 47.2%, 27.2%, and 22.6% in the non-perivascular group. No significant between-group differences were detected in cumulative local tumor progression (p=0.567, hazard ratio: 1.224) or overall survival (p = 0.801, hazard ratio: 1.047). The major complication rate was 1.0% (1/104, p > 0.999) in both groups. Tumor size was the only independent prognostic factor for local tumor progression (hazard ratio: 2.314; p = 0.002). On multivariate analysis for overall colorectal liver metastases, tumor diameter >3 cm, tumor location in the right colon, multiple tumors, and extrahepatic metastases before radiofrequency ablation (hazard ratios: 2.046, 1.920, 1.706, and 1.892, respectively; all p < 0.001) and intrahepatic recurrence (hazard ratio: 1.564; p = 0.002) were associated with poor overall survival.

Cumulative local tumor progression, overall survival, and major complications rates did not differ significantly between perivascular and non-perivascular colorectal liver metastases after percutaneous radiofrequency ablation. For perivascular colorectal liver metastases, percutaneous radiofrequency ablation is a safe and effective treatment option.

• colorectal cancer
• liver metastases
• perivascular locations
• radiofrequency ablation
• treatment outcome

• CT portography
• Carcinoma
• Hepatocellular
• Liver neoplasms
• Microwaves
• Percutaneous treatment

• Bipolar
• Finite element method
• Liver
• Matrix
• Radiofrequency ablation

• Animals
• Cattle
• Electrodes
• Finite Element Analysis
• Liver/pathology
• Liver/surgery
• Liver Neoplasms/pathology
• Liver Neoplasms/surgery
• Radiofrequency Ablation/instrumentation
• Radiofrequency Ablation/methods

• Colorectal liver metastases
• Liver resection
• Microwave ablation
• Radiofrequency ablation

• Ablation Techniques/methods
• Carcinoma/secondary
• Carcinoma/surgery
• Colorectal Neoplasms/pathology
• Cryosurgery/methods
• Disease Progression
• Disease-Free Survival
• Electroporation/methods
• Humans
• Liver Neoplasms/secondary
• Liver Neoplasms/surgery
• Radiofrequency Ablation/methods
• Survival Rate
• Treatment Outcome

• Colon adenocarcinoma
• Overexpression
• Promoter activity
• Stanniocalcin 2
• Transcription factor Sp1

• Adenocarcinoma/genetics
• Adenocarcinoma/mortality
• Adenocarcinoma/pathology
• Cell Line, Tumor
• Colonic Neoplasms/genetics
• Colonic Neoplasms/mortality
• Colonic Neoplasms/pathology
• DNA Methylation/genetics
• Gene Expression Regulation, Neoplastic
• Gene Knockdown Techniques
• Glycoproteins/genetics
• HEK293 Cells
• Humans
• Intercellular Signaling Peptides and Proteins/genetics
• Prognosis
• Promoter Regions, Genetic/genetics
• Signal Transduction/genetics
• Sp1 Transcription Factor/genetics
• Sp1 Transcription Factor/metabolism
• Survival Rate
• Transcriptional Activation
• Up-Regulation